Treatment of congestion in upper respiratory diseases

International Journal of General Medicine

Volumn 3, Issue , 2010, Pages 69-91

  Meltzer, Eli O ^a,b   Caballero, Fernan ^c   Fromer, Leonard M ^d   Krouse, John H ^e   Scadding, Glenis ^f  

^a ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Centro Medico Docente La Trinidad   (Venezuela)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Royal National TNE Hospital   (United Kingdom)

Author keywords

Allergic rhinitis; Congestion; Obstruction; Rhinosinusitis; Treatment

Indexed keywords

ACRIVASTINE; ASTEMIZOLE; AZELASTINE; BECLOMETASONE; BROMPHENIRAMINE; CETIRIZINE; CHLORPHENIRAMINE; CORTICOSTEROID; DECONGESTIVE AGENT; DESLORATADINE; DIPHENHYDRAMINE; EBASTINE; FEXOFENADINE; FLUNISOLIDE; FLUTICASONE PROPIONATE; HISTAMINE H1 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCABASTINE; LEVOCETIRIZINE; LORATADINE; MIZOLASTINE; MOMETASONE FUROATE; MONTELUKAST; OLOPATADINE; PLACEBO; PSEUDOEPHEDRINE; TERFENADINE; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ABDOMINAL PAIN; ABNORMAL BEHAVIOR; ABNORMAL DREAMING; AGGRESSION; AGITATION; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ANXIETY DISORDER; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EAR INFECTION; ETHMOIDECTOMY; HALLUCINATION; HAY FEVER; HUMAN; IMMUNOTHERAPY; INSOMNIA; LIVER DYSFUNCTION; LONG TERM CARE; NAUSEA; NOSE CONGESTION; NOSE POLYP; NOSE SURGERY; PATIENT EDUCATION; PATIENT MONITORING; PERENNIAL RHINITIS; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOSINUSITIS; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TREMOR; UPPER RESPIRATORY TRACT CONGESTION; URINE RETENTION; VASOMOTOR RHINITIS; XEROSTOMIA;

EID: 77953368218     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/ijgm.s8184     Document Type: Review

References (204)

1. Prenner BM, Schenkel E. Allergic rhinitis: treatment based on patient profiles. Am J Med. 2006;119(3):230-237.
2. Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey. Treat Respir Med. 2005;4(6):439-446.
3. Lundbäck B. Epidemiology of rhinitis and asthma. Clin Exp Allergy. 1998;28 Suppl 2:3-10.
4. Hickner JM, Bartlett JG, Besser RE. Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med. 2001;134(6):498-505.
5. Leggett JE. Acute sinusitis. When - and when not -to prescribe antibiotics. Postgrad Med. 2004;115(1):13-19.
6. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl): S147-S334.
7. Fokkens W, Lund V, Mullol J. European position paper on rhinosinusitis and nasal polyps. Rhinol Suppl. 2007;(Suppl 20):1-136.
8. Ratner PH, Howland WC III, Arastu R, et al. Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol. 2003;90(5):536-542.
9. American Academy of Allergy, Asthma and Immunology. Available from: http://www.aaaai.org/members/cme_ce/allergicdisorders/case1.stm. Accessed August 6, 2009.
10. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy. 2000;55(2):116-134.
11. Managing the patient with allergic rhinitis. In: The Allergy Report. Milwaukee, WI: The American Academy of Allergy, Asthma and Immunology; 2000.
12. Canonica GW, Holgate ST, Karlsson G, et al. The impact of allergic rhinitis on quality of life and other airway diseases. Summary of a European conference. Allergy. 1998;53(41 Suppl):1-31.
13. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol. 1998;81(5 Pt 2):478-518.
14. Skoner DP. Treating allergic rhinitis: current challenges and future approaches. Available from: http://www.aaaai.org/members/cme_ce/allergicdisorders/case1.stm. Accessed August 6, 2009.
15. 2005 Gallup Study of Allergies (Phase II Report). A service of Multi-sponsor Surveys, Inc. under a license agreement with The Gallup Organization.
16. Parikh AA, Scadding GK. Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial. Laryngoscope. 2005;115(8): 1385-1390.
17. Blom HM, Van Rijswijk JB, Garrelds IM, Mulder PG, Timmermans T, Gerth van Wijk R. Intranasal capsaicin is efficacious in non-allergic, non-infectious perennial rhinitis. A placebo-controlled study. Clin Exp Allergy. 1997;27(7):796-801.
18. Gerth Van Wijk R, Terreehorst IT, Mulder PG, Garrelds IM, Blom HM, Popering S. Intranasal capsaicin is lacking therapeutic effect in perennial allergic rhinitis to house dust mite. A placebo-controlled study. Clin Exp Allergy. 2000;30(12):1792-1798.
19. Eccles R. Menthol: effects on nasal sensation of airflow and the drive to breathe. Curr Allergy Asthma Rep. 2003;3(3):210-214.
20. Plaut M, Valentine MD. Clinical practice. Allergic rhinitis. N Engl J Med. 2005;353(18):1934-1944.
21. Patanase [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2008.
22. Hore I, Georgalas C, Scadding G. Oral antihistamines for the symptom of nasal obstruction in persistent allergic rhinitis -a systematic review of randomized controlled trials. Clin Exp Allergy. 2005;35(2):207-212.
23. Bertrand B, Jamart J, Marchal JL, Arendt C. Cetirizine and pseudo-ephedrine retard alone and in combination in the treatment of perennial allergic rhinitis: a double-blind multicentre study. Rhinology. 1996;34(2):91-96.
24. Bronsky E, Boggs P, Findlay S, et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Immunol. 1995;96(2):139-147.
25. Pleskow W, Grubbe R, Weiss S, Lutsky B. Efficacy and safety of an extended-release formulation of desloratadine and pseudoephedrine vs the individual components in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2005;94(3):348-354.
26. Sussman GL, Mason J, Compton D, Stewart J, Ricard N. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104(1):100-106.
27. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ. 1998;317(7173):1624-1629.
28. Yáñez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002;89(5): 479-484.
29. Banov CH, Lieberman P; Vasomotor Rhinitis Study Groups. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonal-lergic) rhinitis. Ann Allergy Asthma Immunol. 2001;86(1):28-35.
30. Purello-D'Ambrosio F, Isola S, Ricciardi L, Gangemi S, Barresi L, Bagnato GF. A controlled study on the effectiveness of loratadine in combination with flunisolide in the treatment of nonallergic rhinitis with eosinophilia (NARES). Clin Exp Allergy. 1999;29(8):1143-1147.
31. Braun JJ, Alabert JP, Michel FB, et al. Adjunct effect of loratadine in the treatment of acute sinusitis in patients with allergic rhinitis. Allergy. 1997;52(6):650-655.
32. Haye R, Aanesen JP, Burtin B, Donnelly F, Duby C. The effect of cetirizine on symptoms and signs of nasal polyposis. J Laryngol Otol. 1998;112(11):1042-1046.
33. Mösges R, Klimek L. Azelastine reduces mediators of inflammation in patients with nasal polyps. Allergy Asthma Proc. 1998;19(6): 379-383.
34. Berkowitz RB, Tinkelman DG. Evaluation of oral terfenadine for treat-ment of the common cold. Ann Allergy. 1991;67(6):593-597.
35. Gaffey MJ, Kaiser DL, Hayden FG. Ineffectiveness of oral terfenadine in natural colds: evidence against histamine as a mediator of common cold symptoms. Pediatr Infect Dis J. 1988;7(3):223-228.
36. Muether PS, Gwaltney JM Jr. Variant effect of first-and second-generation antihistamines as clues to their mechanism of action on the sneeze reflex in the common cold. Clin Infect Dis. 2001;33(9): 1483-1488.
37. Gibbs TG, McDonnell KA, Stokes T, Graham AA. Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonal allergic rhinitis. Br J Clin Pract. 1989;43(1):11-14.
38. Howarth PH, Holgate ST. Comparative trial of two non-sedative H1 antihistamines, terfenadine and astemizole, for hay fever. Thorax. 1984;39(9):668-672.
39. Meltzer EO, Storms WW, Pierson WE, et al. Efficacy of azelastine in perennial allergic rhinitis: clinical and rhinomanometric evaluation. J Allergy Clin Immunol. 1988;82(3 Pt 1):447-455.
40. Bousquet J, Gaudaño EM, Palma Carlos AG, Staudinger H. A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis. Multi-centre Study Group. Allergy. 1999;54(6):562-568.
41. Ratner PH, Lim JC, Georges GC. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group. J Allergy Clin Immunol. 2000;105(6 Pt 1):1101-1107.
42. Bachert C, Brostoff J, Scadding GK, Tasman J, Stalla-Bourdillon A, Murrieta M. Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis. RIPERAN Study Group. Allergy. 1998;53(10):969-975.
43. Bruttmann G, Charpin D, Germouty J, Horak F, Kunkel G, Wittmann G. Evaluation of the efficacy and safety of loratadine in perennial allergic rhinitis. J Allergy Clin Immunol. 1989;83(2 Pt 1):411-416.
44. Meltzer EO, Scheinmann P, Rosado Pinto JE, et al. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis -a pooled analysis of three studies. Pediatr Allergy Immunol. 2004;15(3): 253-260.
45. Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 2000;30(6):891-899.
46. Ciprandi G, Cosentino C, Milanese M, Mondino C, Canonica GW. Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy. 2001;56(11):1068-1070.
47. Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofena-dine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104(5):927-933.
48. Mansmann HC Jr, Altman RA, Berman BA, et al. Efficacy and safety of cetirizine therapy in perennial allergic rhinitis. Ann Allergy. 1992;68(4):348-353.
49. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy. 2001;56(11): 1077-1080.
50. Simons FE, Prenner BM, Finn A Jr. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003;111(3):617-622.
51. Leynadier F, Mees K, Arendt C, Pinelli ME. Efficacy and safety of levocetirizine in seasonal allergic rhinitis. Acta Otorhinolaryngol Belg. 2001;55(4):305-312.
52. Bachert C, Bousquet J, Canonica GW, et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol. 2004;114(4):838-844.
53. Berlin JM, Golden SJ, Teets S, Lehman EB, Lucas T, Craig TJ. Efficacy of a steroid nasal spray compared with an antihistamine nasal spray in the treatment of perennial allergic rhinitis. J Am Osteopath Assoc. 2000;100(11 Suppl):S8-S13.
54. Ortolani C, Foresi A, Di Lorenzo G, et al. A double-blind, placebo-controlled comparison of treatment with fluticasone propionate and levocabastine in patients with seasonal allergic rhinitis. FLNCO2 Italian Study Group. Allergy. 1999;54(11):1173-1180.
55. Lange B, Lukat KF, Rettig K, Holtappels G, Bachert C. Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2005;95(3):272-282.
56. Ratner PH, Hampel FC, Amar NJ, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar. Ann Allergy Asthma Immunol. 2005;95(5):474-479.
57. Meltzer EO, Hampel FC, Ratner PH, et al. Safety and efficacy of olopa-tadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2005;95(6):600-606.
58. Wihl JA, Petersen BN, Petersen LN, Gundersen G, Bresson K, Mygind N. Effect of the nonsedative H1-receptor antagonist astemizole in perennial allergic and nonallergic rhinitis. J Allergy Clin Immunol. 1985;75(6):720-727.
59. Géhanno P, Deschamps E, Garay E, Baehre M, Garay RP. Vasomotor rhinitis: clinical efficacy of azelastine nasal spray in comparison with placebo. ORL J Otorhinolaryngol Relat Spec. 2001;63(2):76-81.
60. van de Heyning PH, van Haesendonck J, Creten W, Rombaut N. Effect of topical levocabastine on allergic and non-allergic perennial rhinitis. A double-blind study, levocabastine vs placebo, followed by an open, prospective, single-blind study on beclomethasone. Allergy. 1988;43(5):386-391.
61. Berkowitz RB, Connell JT, Dietz AJ, Greenstein SM, Tinkelman DG. The effectiveness of the nonsedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Ann Allergy. 1989;63(4):336-339.
62. Clemens CJ, Taylor JA, Almquist JR, Quinn HC, Mehta A, Naylor GS. Is an antihistamine-decongestant combination effective in temporarily relieving symptoms of the common cold in preschool children? J Pediatr. 1997;130(3):463-466.
63. Hutton N, Wilson MH, Mellits ED, et al. Effectiveness of an antihistamine-decongestant combination for young children with the common cold: a randomized, controlled clinical trial. J Pediatr. 1991;118(1): 125-130.
64. Welch MJ, Meltzer EO, Simons FE. H1-antihistamines and the central nervous system. Clin Allergy Immunol. 2002;17:337-388.
65. Rodrigo GJ, Yañez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol. 2006;96(6):779-786.
66. Donnelly AL, Glass M, Minkwitz MC, Casale TB. The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med. 1995;151(6):1734-1739.
67. Pullerits T, Praks L, Skoogh BE, Ani R, Lötvall J. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Respir Crit Care Med. 1999;159(6):1814-1818.
68. Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med. 1990;323(25):1745-1748.
69. Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002;32(7):1020-1028.
70. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol. 2000;105(5): 917-922.
71. Moinuddin R, deTineo M, Maleckar B, Naclerio RM, Baroody FM. Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2004;92(1):73-79.
72. Patel P, Philip G, Yang W, et al. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2005;95(6):551-557.
73. Martin BG, Andrews CP, van Bavel JH, et al. Comparison of fluticasone propionate aqueous nasal spray and oral montelukast for the treatment of seasonal allergic rhinitis symptoms. Ann Allergy Asthma Immunol. 2006;96(6):851-857.
74. Nathan RA, Yancey SW, Waitkus-Edwards K, et al. Fluticasone propio-nate nasal spray is superior to montelukast for allergic rhinitis while nei-ther affects overall asthma control. Chest. 2005;128(4):1910-1920.
75. Mostafa BE, Abdel Hay H, Mohammed HE, Yamani M. Role of leu-kotriene inhibitors in the postoperative management of nasal polyps. ORL J Otorhinolaryngol Relat Spec. 2005;67(3):148-153.
76. Ulualp SO, Sterman BM, Toohill RJ. Antileukotriene therapy for the relief of sinus symptoms in aspirin triad disease. Ear Nose Throat J. 1999;78:604-606, 608, 613, passim.
77. Harmanci K. Montelukast: its role in the treatment of childhood asthma. Ther Clin Risk Manag. 2007;3(5):885-892.
78. Bisgaard H. Leukotriene modifiers in pediatric asthma management. Pediatrics. 2001;107(2):381-390.
79. Salvi SS, Krishna MT, Sampson AP, Holgate ST. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest. 2001;119(5):1533-1546.
80. FDA. Leukotriene inhibitors: montelukast (marketed as singulair), zafirlukast (marketed as Accolate), and zileuton (marketed as Zyflo and Zyflo CR). August 28, 2009. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts//ucm16624.htm.
81. Singulair (montelukast sodium) [package insert]. Whitehouse Station, NJ: Merck and Co; 2009. Available at: http://www.merck.com/product/usa/pi_circulars/s/singulair/singulair_pi.pdf. Accessed December 4, 2009.
82. Ramey JT, Bailen E, Lockey RF. Rhinitis medicamentosa. J Investig Allergol Clin Immunol. 2006;16(3):148-155.
83. Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of rhinosinusitis and nasal polyposis. Clin Exp Allergy. 2007;38:260-275.
84. Thomas M, Yawn BP, Price D, Lund V, Mullol J, Fokkens W. EPOS Primary Care Guidelines: European Position Paper on the Primary Care Diagnosis and Management of Rhinosinusitis and Nasal Polyps 2007 -a summary. Prim Care Respir J. 2008;17(2):79-89.
85. Selner JC, Koepke JW, Staudenmayer H, et al. Assessment of nasal patency by rhinoscopic measurement of cross sectional nasal air-way area: correlation with subjective nasal symptoms. Ann Allergy. 1991;66(1):43-47.
86. Stübner UP, Toth J, Marks B, Berger UE, Burtin B, Horak F. Efficacy and safety of an oral formulation of cetirizine and prolonged-release pseudoephedrine versus xylometazoline nasal spray in nasal congestion. Arzneimittelforschung. 2001;51(11):904-910.
87. Barnes ML, Biallossterski BT, Gray RD, Fardon TC, Lipworth BJ. Decongestant effects of nasal xylometazoline and mometasone furoate in persistent allergic rhinitis. Rhinology. 2005;43:291-295.
88. Mucha SM, deTineo M, Naclerio RM, Baroody FM. Comparison of montelukast and pseudoephedrine in the treatment of allergic rhinitis. Arch Otolaryngol Head Neck Surg. 2006;132(2):164-172.
89. Grosclaude M, Mees K, Pinelli ME, Lucas M, Van de Venne H. Cetirizine and pseudoephedrine retard, given alone or in combination, in patients with seasonal allergic rhinitis. Rhinology. 1997;35(2): 67-73.
90. Chervinsky P, Nayak A, Rooklin A, Danzig M. Efficacy and safety of desloratadine/pseudoephedrine tablet, 2.5/120 mg two times a day, versus individual components in the treatment of patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2005;26(5):391-396.
91. Caenen M, Hamels K, Deron P, Clement P. Comparison of decongestive capacity of xylometazoline and pseudoephedrine with rhinomanometry and MRI. Rhinology. 2005;43(3):205-209.
92. McCormick DP, John SD, Swischuk LE, Uchida T. A double-blind, placebo-controlled trial of decongestant-antihistamine for the treatment of sinusitis in children. Clin Pediatr (Phila). 1996;35(9):457-460.
93. Taverner D, Latte J. Nasal decongestants for the common cold. Cochrane Database Syst Rev. 2007;24(1):CD001953.
94. Eccles R, Jawad MS, Jawad SS, Angello JT, Druce HM. Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. Am J Rhinol. 2005;19(1):25-31.
95. Akerlund A, Klint T, Olén L, Rundcrantz H. Nasal decongestant effect of oxymetazoline in the common cold: an objective dose-response study in 106 patients. J Laryngol Otol. 1989;103(8):743-746.
96. The Combat Meth Act of 2005. US Department of Justice Drug Enforcement Administration, Office of Diversion Control. Available from: http://www.deadiversion.usdoj.gov/meth/q_a.htm#3_cmea_req. Accessed August 6, 2009.
97. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med. 2004;116(5):338-344.
98. Creticos P, Fireman P, Settipane G, Bernstein D, Casale T, Schwartz H. Intranasal budesonide aqueous pump spray (Rhinocort Aqua) for the treatment of seasonal allergic rhinitis. Rhinocort Aqua Study Group. Allergy Asthma Proc. 1998;19(5):285-294.
99. Ratner PH, Paull BR, Findlay SR, et al. Fluticasone propionate given once daily is as effective for seasonal allergic rhinitis as beclometha-sone dipropionate given twice daily. J Allergy Clin Immunol. 1992; 90(3 Pt 1):285-291.
100. Berger WE, Nayak AS, Staudinger HW. Mometasone furoate improves congestion in patients with moderate-to-severe seasonal allergic rhinitis. Ann Pharmacother. 2005;39(12):1984-1989.
101. Rosenthal R, Berger W, Bronsky E, et al. Tri-Nasal triamcinolone acetonide nasal spray 200 and 400 micrograms qd versus placebo and Nasacort triamcinolone acetonide nasal aerosol 440 micrograms qd in patients suffering from seasonal allergic rhinitis during the grass season. Am J Rhinol. 1998;12(6):427-433.
102. Kaiser HB, Naclerio RM, Given J, Toler TN, Ellsworth A, Philpot EE. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;119(6):1430-1437.
103. Ratner PH, Wingertzahn MA, van Bavel JH, et al. Effectiveness of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97(5):657-663.
104. Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate therapy in children. Fluticasone Propionate Collaborative Pediatric Working Group. J Pediatr. 1994;125(4): 628-634.
105. Meltzer EO, Berger WE, Berkowitz RB, et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104(1):107-114.
106. Graft D, Aaronson D, Chervinsky P, et al. A placebo-and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol. 1996;98(4):724-731.
107. Mandl M, Nolop K, Lutsky BN. Comparison of once daily mometa-sone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. 194-079 Study Group. Ann Allergy Asthma Immunol. 1997;79(4):370-378.
108. Chervinsky P, Kunjibettu S, Miller DL, et al. Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2007;99(1):69-76.
109. Meltzer EO, Kunjibettu S, Hall N, et al. Efficacy and safety of ciclesonide, 200 microg once daily, for the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2007;98(2):175-181.
110. Máspero JF, Rosenblut A, Finn A Jr, Lim J, Wu W, Philpot E. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol Head Neck Surg. 2008;138(1):30-37.
111. Data on file. Kenilworth, New Jersey: Schering Corporation. Protocol No. I96-090.
112. Webb DR, Meltzer EO, Finn AF Jr, et al. Intranasal fluticasone propionate is effective for perennial nonallergic rhinitis with or without eosinophilia. Ann Allergy Asthma Immunol. 2002;88(4):385-390.
113. GlaxoSmithKline. Data on file. Study No. FLN-351. Available from: http://ctr.gsk.co.uk/Summary/fluticasone_propionate/studylist.asp. Accessed August 6, 2009.
114. Meltzer EO, Charous BL, Busse WW, Zinreich SJ, Lorber RR, Danzig MR. Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray. The Nasonex Sinusitis Group. J Allergy Clin Immunol. 2000;106(4):630-637.
115. Meltzer EO, Orgel HA, Backhaus JW, et al. Intranasal flunisolide spray as an adjunct to oral antibiotic therapy for sinusitis. J Allergy Clin Immunol. 1993;92(6):812-823.
116. Nayak AS, Settipane GA, Pedinoff A, et al. Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Ann Allergy Asthma Immunol. 2002;89(3):271-278.
117. Dolor RJ, Witsell DL, Hellkamp AS, Williams JW Jr, Califf RM, Simel DL; Ceftin and Flonase for Sinusitis (CAFFS) Investigators. Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis. The CAFFS Trial: a randomized controlled trial. JAMA. 2001;286(24):3097-3105.
118. Barlan IB, Erkan E, Bakir M, Berrak S, Ba ̧aran MM. Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children. Ann Allergy Asthma Immunol. 1997;78(6):598-601.
119. Yilmaz G, Varan B, Yilmaz T, Gürakan B. Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children. Eur Arch Otorhinolaryngol. 2000;257(5):256-259.
120. Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxi-cillin, and placebo. J Allergy Clin Immunol. 2005;116(6):1289-1295.
121. Lund VJ, Black JH, Szabó LZ, Schrewelius C, Akerlund A. Efficacy and tolerability of budesonide aqueous nasal spray in chronic rhino-sinusitis patients. Rhinology. 2004;42(2):57-62.
122. Holmberg K, Juliusson S, Balder B, Smith DL, Richards DH, Karlsson G. Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis. Ann Allergy Asthma Immunol. 1997;78(3):270-276.
123. Lund VJ, Flood J, Sykes AP, Richards DH. Effect of fluticasone in severe polyposis. Arch Otolaryngol Head Neck Surg. 1998;124(5): 513-518.
124. Small CB, Hernandez J, Reyes A, et al. Efficacy and safety of mometa-sone furoate nasal spray in nasal polyposis. J Allergy Clin Immunol. 2005;116(6):1275-1281.
125. Stjärne P, Mösges R, Jorissen M, et al. A randomized controlled trial of mometasone furoate nasal spray for the treatment of nasal polyposis. Arch Otolaryngol Head Neck Surg. 2006;132(2):179-185.
126. Keith P, Nieminen J, Hollingworth K, Dolovich J. Efficacy and toler-ability of fluticasone propionate nasal drops 400 microgram once daily compared with placebo for the treatment of bilateral polyposis in adults. Clin Exp Allergy. 2000;30(10):1460-1468.
127. Scadding GK. Comparison of medical and surgical treatment of nasal polyposis. Curr Allergy Asthma Rep. 2002;2(6):494-499.
128. Puhakka T, Mäkelä MJ, Malmström K, et al. The common cold: effects of intranasal fluticasone propionate treatment. J Allergy Clin Immunol. 1998;101(6 Pt 1):726-731.
129. Qvarnberg Y, Valtonen H, Laurikainen K. Intranasal beclometha-sone dipropionate in the treatment of common cold. Rhinology. 2001;39(1):9-12.
130. Flixonase [package insert]. Brentford, Middlesex, UK: GlaxoSmithKline; 2008.
131. Nasonex [package insert]. Kenilworth, NJ: Schering-Plough Corporation; 2005.
132. Veramyst [package insert]. Research Triangle Park, NC: GlaxoSmith-Kline; 2007.
133. Rhinocort [package insert]. Wilmington, DE: AstraZeneca LP; 2005.
134. Beconase [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2005.
135. Nasacort [package insert]. Bridgewater, NJ: Sanofi-aventis; 2008.
136. Argenti D, Shah B, Heald D. A pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration. J Clin Pharmacol. 1999;39(7):695-702.
137. Allen DB. Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol. 2000;106(4 Suppl): S179-S190.
138. Brannan MD, Seiberling M, Cutler DL, Cuss FM, Affrime MB. Lack of systemic activity with intranasal mometasone furoate [abstract]. J Allergy Clin Immunol. 1996;97(1):198.
139. Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther. 1997;19(6):1330-1339.
140. Skoner DP, Gentile D, Angelini B, Kane R, Birdsall D, Banerji D. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2003;90(1):56-62.
141. Bachert C, Lukat KF, Lange B. Effect of intranasal fluticasone propionate and triamcinolone acetonide on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity in healthy volunteers. Clin Exp Allergy. 2004;34(1):85-90.
142. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclometha-sone dipropionate. Pediatrics. 2000;105(2):E23.
143. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000;105(2):E22.
144. Minshall E, Ghaffar O, Cameron L, et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg. 1998;118(5):648-654.
145. Klossek JM, Laliberté F, Laliberté MF, Mounedji N, Bousquet J. Local safety of intranasal triamcinolone acetonide: clinical and histological aspects of nasal mucosa in the long-term treatment of perennial allergic rhinitis. Rhinology. 2001;39(1):17-22.
146. Holgate ST. Reflections on the mechanism(s) of action of sodium cromoglycate (Intal) and the role of mast cells in asthma. Respir Med. 1989;83(Suppl A):25-31.
147. Ratner PH, Ehrlich PM, Fineman SM, Meltzer EO, Skoner DP. Use of intranasal cromolyn sodium for allergic rhinitis. Mayo Clin Proc. 2002;77(4):350-354.
148. Ogata N, Darby Y, Scadding G. Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma. J Laryngol Otol. 2007;121(12):1156-1160.
149. Meltzer EO, Orgel HA, Bronsky EA, et al. Ipratropium bromide aqueous nasal spray for patients with perennial allergic rhinitis: a study of its effect on their symptoms, quality of life, and nasal cytology. J Allergy Clin Immunol. 1992;90(2):242-249.
150. Kirkegaard J, Mygind N, Mølgaard F, et al. Ordinary and high-dose ipratropium in perennial nonallergic rhinitis. J Allergy Clin Immunol. 1987;79(4):585-590.
151. Atrovent nasal aqueous [package insert]. Auckland, NZ: Boehringer Ingelheim (NZ) Ltd; 2003.
152. Brooks CD, Karl KJ, Francom SF. Oral methylprednisolone acetate (Medrol Tablets) for seasonal rhinitis: examination of dose and symptom response. J Clin Pharmacol. 1993;33(9):816-822.
153. Brooks CD, Titus CR, Heissler CT. Vasoconstrictor and corticosteroid responsive components of allergic nasal mucosal swelling. Ann Allergy. 1988;61(2):151-156.
154. Hissaria P, Smith W, Wormald PJ, et al. Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures. J Allergy Clin Immunol. 2006;118:128-133.
155. Lacroix JS, Buvelot JM, Polla BS, Lundberg JM. Improvement of symptoms of non-allergic chronic rhinitis by local treatment with capsaicin. Clin Exp Allergy. 1991;21(5):595-600.
156. Eccles R, Jawad MS, Morris S. The effects of oral administration of (-)-menthol on nasal resistance to airflow and nasal sensation of airflow in subjects suffering from nasal congestion associated with the common cold. J Pharm Pharmacol. 1990;42(9):652-654.
157. Wallace DV, Dykewicz, Bernstein DI, et al; for the Joint Task Force on Practice Parameter for Allergy and Immunology. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(suppl 2); S1-S84.
158. Harvey R, Hannan SA, Badia L, Scadding G. Nasal saline irrigations for the symptoms of chronic rhinosinusitis. Cochrane Database Syst Rev. 2007;18(3):CD006394.
159. Wang YH, Yang CP, Ku MS, Sun HL, Lue KH. Efficacy of nasal irrigation in the treatment of acute sinusitis in children. Int J Pediatr Otorhinolaryngol. 2009;73(12):1696-1701.
160. Rabago D, Zgierska A, Mundt M, Barret B, Bobula J, Maberry R. Efficacy of daily hypertonic saline nasal irrigation among patients with sinusitis: a randomized controlled trial. J Fam Pract. 2002;51(12); 1049-1055.
161. Ciprandi G, Passalacqua G. Emerging anti-inflammatory agents for allergic rhinitis. Expert Opin Emerg Drugs. 2005;10(4):689-705.
162. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;118(2):434-440.
163. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy. 2005;60(1):4-12.
164. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341(7): 468-475.
165. D'Amato G, Kordash TR, Liccardi G, Lobefalo G, Cazzola M, Fresh-water LL. Immunotherapy with Alpare in patients with respiratory allergy to Parietaria pollen: a two year double-blind placebo-controlled study. Clin Exp Allergy. 1995;25(2):149-158.
166. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Use-fulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ. 1991;302(6771):265-269.
167. Van Deusen MA, Angelini BL, Cordoro KM, Seiler BA, Wood L, Skoner DP. Efficacy and safety of oral immunotherapy with short rag-weed extract. Ann Allergy Asthma Immunol. 1997;78(6):573-580.
168. Durham SR, Riis B. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy. 2007;62(8):954-957.
169. Calderon MA, Birk AO, Andersen JS, Durham SR. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy. 2007;62(8):958-961.
170. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120(6):1338-1345.
171. Tonnel AB, Scherpereel A, Douay B, et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy. 2004;59(5):491-497.
172. Kemker B, Liu X, Gungor A, Moinuddin R, Corey JP. Effect of nasal surgery on the nasal cavity as determined by acoustic rhinometry. Otolaryngol Head Neck Surg. 1999;121(5):567-571.
173. Konstantinidis I, Triaridis S, Triaridis A, Karagiannidis K, Kontzoglou G. Long term results following nasal septal surgery. Focus on patients' satisfaction. Auris Nasus Larynx. 2005;32(4):369-374.
174. Stewart MG, Smith TL, Weaver EM, et al. Outcomes after nasal sep-toplasty: results from the Nasal Obstruction Septoplasty Effectiveness (NOSE) study. Otolaryngol Head Neck Surg. 2004;130(3):283-290.
175. Murakami C. Nasal valve collapse. Ear Nose Throat J. 2004;83(3): 163-164.
176. Hol MK, Huizing EH. Treatment of inferior turbinate pathology: a review and critical evaluation of the different techniques. Rhinology. 2000;38(4):157-166.
177. Cavaliere M, Mottola G, Iemma M. Comparison of the effectiveness and safety of radiofrequency turbinoplasty and traditional surgical technique in treatment of inferior turbinate hypertrophy. Otolaryngol Head Neck Surg. 2005;133(6):972-978.
178. Huang TW, Cheng PW. Changes in nasal resistance and quality of life after endoscopic microdebrider-assisted inferior turbinoplasty in patients with perennial allergic rhinitis. Arch Otolaryngol Head Neck Surg. 2006;132(9):990-993.
179. Wexler D, Braverman I. Partial inferior turbinectomy using the micro-debrider. J Otolaryngol. 2005;34(3):189-193.
180. Lee JY, Lee JD. Comparative study on the long-term effectiveness between coblation-and microdebrider-assisted partial turbinoplasty. Laryngoscope. 2006;116(5):729-734.
181. Dawes PJ. The early complications of inferior turbinectomy. J Laryngol Otol. 1987;101(11):1136-1139.
182. Kim YK, Kang JH, Yoon KS. Acoustic rhinometric evaluation of nasal cavity and nasopharynx after adenoidectomy and tonsillectomy. Int J Pediatr Otorhinolaryngol. 1998;44(3):215-220.
183. Vandenberg SJ, Heatley DG. Efficacy of adenoidectomy in relieving symptoms of chronic sinusitis in children. Arch Otolaryngol Head Neck Surg. 1997;123(7):675-678.
184. Bhattacharyya N. Symptom outcomes after endoscopic sinus surgery for chronic rhinosinusitis. Arch Otolaryngol Head Neck Surg. 2004;130(3):329-333.
185. Numminen J, Dastidar P, Rautiainen M. Influence of sinus surgery in rhinometric measurements. J Otolaryngol. 2004;33(2):98-103.
186. Smith TL, Mendolia-Loffredo S, Loehrl TA, Sparapani R, Laud PW, Nattinger AB. Predictive factors and outcomes in endoscopic sinus surgery for chronic rhinosinusitis. Laryngoscope. 2005;115(12): 2199-2205.
187. Sipilä J, Antila J, Suonpää J. Pre-and postoperative evaluation of patients with nasal obstruction undergoing endoscopic sinus surgery. Eur Arch Otorhinolaryngol. 1996;253(4-5):237-239.
188. Bunnag C, Jareoncharsri P, Wong EC. A doubleblind comparison of nasal budesonide and oral astemizole for the treatment of perennial rhinitis. Allergy. 1992;47(4 Pt 1):313-317.
189. Simpson RJ. Budesonide and terfenadine, separately and in combination, in the treatment of hay fever. Ann Allergy. 1994;73(6): 497-502.
190. Brooks CD, Francom SF, Peel BG, Chene BL, Klott KA. Spectrum of seasonal allergic rhinitis symptom relief with topical corticoid and oral antihistamine given singly or in combination. Am J Rhinol. 1996;10:193-199.
191. Bernstein DI, Creticos PS, Busse WW, Cohen R, Graft DF, Howland WC, et al. Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweedinduced allergic rhinitis. J Allergy Clin Immunol. 1996;97(3):749-755.
192. Schoenwetter W, Lim J. Comparison of intranasal triamcinolone acetonide with oral loratadine for the treatment of patients with seasonal allergic rhinitis. Clin Ther. 1995;17(3):479-492.
193. Vervloet D, Charpin D, Desfougeres JL. Intranasal fluticasone once daily compared with once daily cetirizine in the treatment of seasonal allergic rhinitis. Clin Drug Invest. 1997;13:291-298.
194. Bronsky EA, Dockhorn RJ, Meltzer EO, Shapiro G, Boltansky H, LaForce C, et al. Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 1996;97(4):915-921.
195. Munch EP, Soborg M, Norreslet TT, Mygind N. A comparative study of dexchlorpheniramine maleate sustained release tablets and budesonide nasal spray in seasonal allergic rhinitis. Allergy. 1983;38(7):517-524.
196. Géhanno P, Desfougeres JL. Fluticasone propionate aqueous nasal spray compared with oral loratadine in patients with seasonal allergic rhinitis. Allergy. 1997;52(4):445-450.
197. Juniper EF, Kline PA, Hargreave FE, Dolovich J. Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol. 1989;83(3):627-633.
198. Darnell R, Pecoud A, Richards DH. A double-blind comparison of fluticasone propionate aqueous nasal spray, terfenadine tablets and placebo in the treatment of patients with seasonal allergic rhinitis to grass pollen. Clin Exp Allergy. 1994;24(12):1144-1150.
199. Beswick KB, Kenyon GS, Cherry JR. A comparative study of beclo-methasone dipropionate aqueous nasal spray with terfenadine tablets in seasonal allergic rhinitis. Curr Med Res Opin. 1985;9(8):560-567.
200. Wood SF. Oral antihistamine or nasal steroid in hay fever; a double-blind double-dummy comparative study of once daily oral astemizole vs twice daily nasal beclomethasone dipropionate. Clin Allergy. 1986;16(3):195-201.
201. Robinson AC, Cherry JR, Daly S. Double-blind crossover trial compar-ing beclomethasone dipropionate and terfenadine in perennial rhinitis. Clin Exp Allergy. 1989;19(5):569-573.
202. Davies RJ, Lund VJ, Harten-Ash VJ. The effect of intranasal azelastine and beclomethasone on the symptoms and signs of nasal allergy in patients with perennial allergic rhinitis. Rhinology. 1993;31(4):159-164.
203. Di Lorenzo G, Gervasi F, Drago A, et al. Comparison of the effects of fluticasone propionate, aqueous nasal spray and levocabastine on inflammatory cells in nasal lavage and clinical activity during the pollen season in seasonal rhinitis. Clin Exp Allergy. 1999;29(10):1367-1377.
204. Stern MA, Wade AG, Ridout SM, Cambell LM. Nasal budesonide offers superior symptom relief in perennial allergic rhinitis in comparison to nasal azelastine. Ann Allergy Asthma Immunol. 1998;81(4):354-358.